New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
07:21 EDTPFE, MDT, BMY, NVS, JNJ, BAYRY, SNY, MRK, GILD, BAXFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 >>
November 16, 2015
09:04 EDTGILDGilead says Phase 3 Zydelig study shows 'clinical benefit'
Gilead announced that its Phase 3 Study 115 evaluating Zydelig added to standard therapy in previously-treated chronic lymphocytic leukemia patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival and overall survival in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in Orlando, Florida taking place December 5-8. "The clinical benefit observed in this Phase 3 study adds to the body of evidence demonstrating the potential of Zydelig-containing treatment regimens for patients with previously treated CLL," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to sharing the detailed scientific data with the hematology community at the upcoming ASH meeting."
08:35 EDTMRKMerck to present Phase 2 hep C therapy data at The Liver Meeting
Subscribe for More Information
07:24 EDTMRKSalomon to hold a conference
Subscribe for More Information
07:00 EDTBMYBristol-Myers announces data from Phase 3 ALLY-3+ trial for Daklinza
Bristol-Myers announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a regimen of Daklinza in combination with sofosbuvir and ribavirin in genotype 3 hepatitis C patients with advanced fibrosis or cirrhosis, for treatment durations of 12 and 16 weeks. This patient population is one of the most difficult to treat, among whom sustained virologic response rates, or cure, have proved harder to achieve. The results show that 100% of patients in the advanced fibrosis cohort achieved SVR12 in both the 12- and 16-week arms of the study. SVR12 rates were 83% and 89% in patients with cirrhosis in the 12- and 16-week arms, respectively.
06:33 EDTPFEPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
06:11 EDTBAXBaxter resumed with a Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Brooks West downgraded Baxter (BAX) to Neutral after resuming coverage of the name. The company, post the spin of Baxalta (BXLT), "has a number of moving pieces that need to be addressed," West tells investors in a research note. He lowered his price target for shares to $39 from $90.
November 15, 2015
20:17 EDTGILDGilead presents results from four Phase 3 studies of sofosbuvir/velpatasvir
Subscribe for More Information
18:13 EDTPFEAllergan, Pfizer targeting late November merger deal, FT says
Subscribe for More Information
15:47 EDTGILDGilead reports data from multiple studies of Viread, TAF, others
Subscribe for More Information
15:19 EDTMRKMerck reports integrated analysis of six trials of elbasvir/grazoprevir
Subscribe for More Information
15:15 EDTMRKMerck reports Phase 3 data on elbasvir/grazoprevir in patients injecting drugs
Subscribe for More Information
13:04 EDTBAYRYBayer shares could advance 25% in a year, Barron's says
Subscribe for More Information
November 13, 2015
17:04 EDTBAXThird Point gives quarterly update on stakes
Subscribe for More Information
13:57 EDTPFEAppeals court vacates decision invalidating Medicines Co. Angiomax patents
Subscribe for More Information
11:12 EDTPFEPiper sees Pfizer profiting from Allergan deal, worth $50/share even without one
An acquisition of Allergan (AGN) by Pfizer (PFE) would increase the latter company's profits in 2016-2017 and lift its earnings by a large amount by 2019, wrote research firm Piper Jaffray in a note to investors today. WHAT'S NEW: By 2019, an acquisition of Allergan would increase Pfizer's earnings per share by 13%-16%, estimated Piper analyst Richard Purkiss. The deal would be profitable for Pfizer as early as 2016, the analyst believes. Excluding any acquisition, Pfizer is worth over $50 per share, well above analysts' average price target of $40, Purkiss believes. He kept a $52 price target and Overweight rating on Pfizer. WHAT'S NOTABLE: Yesterday dealReporter, noting that an acquisition of Allergan by Pfizer would be "a giant inversion deal," asserted that the U.S. Treasury could look to take steps to limit or discourage those types of transactions. On November 6, research firm Bernstein said that Allergan's strong results, coupled with the weakness of drug stocks, could cause Allergan to be reluctant to sell itself to Pfizer in the near-term. As a result, the firm thinks that the odds of a deal getting done may be lower than many believe. It kept a $385 price target and Outperform rating on Allergan. PRICE ACTION: In late morning trading, Pfizer rose fractionally to $33.47 and Allergan added 1.3% to $303.87.
10:00 EDTMDTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AB InBev (BUD) upgraded to Buy from Hold at Berenberg... Air Lease (AL) upgraded to Overweight from Neutral at JPMorgan... Aircastle (AYR) upgraded to Neutral from Underweight at JPMorgan... AmTrust (AFSI) upgraded to Buy from Neutral at Compass Point... Anadarko (APC) upgraded to Focus List from Outperform at Scotia Howard Weil... BAE Systems (BAESY) upgraded to Neutral from Underweight at JPMorgan... Bill Barrett (BBG) upgraded to Outperform from Sector Perform at Scotia Howard Weil... Extra Space Storage (EXR) upgraded to Strong Buy from Outperform at Raymond James... Medtronic (MDT) upgraded to Conviction Buy from Buy at Goldman... Mylan (MYL) upgraded to Buy from Neutral at Citi... Scripps Networks (SNI) upgraded to Outperform from Underperform at CLSA... Toll Brothers (TOL) upgraded to Overweight from Neutral at JPMorgan... Wal-Mart (WMT) upgraded to Buy from Neutral at Northcoast... Weir Group (WEIGY) upgraded to Buy from Hold at Deutsche Bank... Weyerhaeuser (WY) upgraded to Outperform from Underperform at CLSA... Yelp (YELP) upgraded to Outperform from Sector Perform at RBC Capital.
08:02 EDTMRKMerck: DMC recommends anacetrapib study continue with no changes
Subscribe for More Information
06:54 EDTPFEPiper sees Pfizer worth over $50/share on standalone basis
Subscribe for More Information
06:26 EDTMDTAbbott downgraded to Neutral from Buy at Goldman
Subscribe for More Information
06:24 EDTMDTMedtronic upgraded to Conviction Buy from Buy at Goldman
Goldman Sachs analyst David Roman upgraded Medtronic (MDT) to Conviction Buy saying the stock's risk/reward is compelling at current levels. The company's fundamentals are the strongest in nearly a decade amid improving end-markets, new product launches and financial flexibility, Roman tells investors in a research note. He raised his price target for shares to $90 from $87. Roman removed Stryker (SYK) from the Conviction List and also downgraded Abbott (ABT) to Neutral.
1 | 2 | 3 | 4 | 5 | 6 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use